{"title":"Comparison of the effect of ranibizumab in retinal vein occlusion and macular edema with different optical coherence tomographic patterns.","authors":"Yue Xu, Yue-Cong Yin, Ze-Yu Song, Xiao-Yu Zhou, Jia-Ju Zhang, Juan Liang","doi":"10.18240/ijo.2025.02.11","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To explore the morphological and functional parameters to evaluate the effectiveness of intravitreal injections of ranibizumab (IVR) in treating macular edema (ME) secondary to retinal vein occlusion (RVO).</p><p><strong>Methods: </strong>This retrospective study involved 65 RVO patients (65 eyes) who received IVR and were followed-up for more than 3mo. ME was categorized into cystoid macular edema (CME), diffuse retinal thickening (DRT), and serous retinal detachment (SRD) according to optical coherence tomography (OCT) images. The comparison of best corrected visual acuity (BCVA; logMAR) and central macular thickness (CMT) among different follow-up points and those among 3 groups were performed by Kruskal-Wallis test. The correlation between BCVA and baseline parameters during treatment was analyzed using Spearman correlation analysis.</p><p><strong>Results: </strong>BCVA tended to improve in all groups, with marked improvement in CME and DRT groups. CMT showed the greatest reduction after 1wk, and remained stable over the following 3mo. DRT patients had the worst BCVA and the highest CMT at baseline, but the differences became smaller after IVR treatment. CMT in SRD group was significantly better than in CME and DRT groups 3mo after IVR. Most patients of CME and SRD groups transitioned to a normal pattern at 3mo follow-up. DRT patients were most likely to transform into the other morphological groups, while SRD patients showed minimal transitions. BCVA at baseline was identified as the most important prognostic indicator in all 3 groups. Additionally, DRT patients with a longer clinical course, higher CMT and central retinal vein occlusion (CRVO) tend to exhibit worse BCVA after treatment. In addition, CRVO patients are more likely to have worse BCVA at 2 and 3mo follow-up compared with branch retinal vein occlusion (BRVO) patients in CME group. SRD patients with higher baseline CMT were prone to experiencing worse BCVA after treatment.</p><p><strong>Conclusion: </strong>The effectiveness of IVR is strongly correlated with baseline BCVA in all 3 groups. Baseline parameters including clinical course, CMT, and RVO position are also useful in predicting the BCVA at different time points after treatment.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 2","pages":"275-282"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754018/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.02.11","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To explore the morphological and functional parameters to evaluate the effectiveness of intravitreal injections of ranibizumab (IVR) in treating macular edema (ME) secondary to retinal vein occlusion (RVO).
Methods: This retrospective study involved 65 RVO patients (65 eyes) who received IVR and were followed-up for more than 3mo. ME was categorized into cystoid macular edema (CME), diffuse retinal thickening (DRT), and serous retinal detachment (SRD) according to optical coherence tomography (OCT) images. The comparison of best corrected visual acuity (BCVA; logMAR) and central macular thickness (CMT) among different follow-up points and those among 3 groups were performed by Kruskal-Wallis test. The correlation between BCVA and baseline parameters during treatment was analyzed using Spearman correlation analysis.
Results: BCVA tended to improve in all groups, with marked improvement in CME and DRT groups. CMT showed the greatest reduction after 1wk, and remained stable over the following 3mo. DRT patients had the worst BCVA and the highest CMT at baseline, but the differences became smaller after IVR treatment. CMT in SRD group was significantly better than in CME and DRT groups 3mo after IVR. Most patients of CME and SRD groups transitioned to a normal pattern at 3mo follow-up. DRT patients were most likely to transform into the other morphological groups, while SRD patients showed minimal transitions. BCVA at baseline was identified as the most important prognostic indicator in all 3 groups. Additionally, DRT patients with a longer clinical course, higher CMT and central retinal vein occlusion (CRVO) tend to exhibit worse BCVA after treatment. In addition, CRVO patients are more likely to have worse BCVA at 2 and 3mo follow-up compared with branch retinal vein occlusion (BRVO) patients in CME group. SRD patients with higher baseline CMT were prone to experiencing worse BCVA after treatment.
Conclusion: The effectiveness of IVR is strongly correlated with baseline BCVA in all 3 groups. Baseline parameters including clinical course, CMT, and RVO position are also useful in predicting the BCVA at different time points after treatment.
期刊介绍:
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.